by InSitu Biologics | Dec 22, 2022 | News & Updates
InSitu Biologics is pleased to announce that it has entered into an agreement with the Mayo Clinic to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics. For more details regarding this announcement, please take some time to...
by InSitu Biologics | Nov 17, 2022 | News & Updates
InSitu Biologics will share the latest investigational work on its multi-phase drug delivery matrix at the upcoming 21st Annual Pain Medicine Meeting of the American Society of Regional Anesthesia on November 18th, 2022. For more details regarding this announcement,...
by InSitu Biologics | Apr 22, 2022 | News & Updates, Uncategorized
InSitu Biologics is very pleased to announce the appointment of Dr. M. Yaman, FRCS, FACS, to its Medical Advisory Board. For more details regarding this announcement, please take some time to read the below press release. Click Here to...
by InSitu Biologics | Mar 30, 2022 | News & Updates
InSitu Biologics will share the latest investigational work on its hydrogel-lipid-microparticle matrix at the upcoming 47th Annual Regional and Acute Pain Medicine Meeting of the American Society of Regional Anesthesia in April 2022. For more details regarding this...
by InSitu Biologics | Mar 14, 2022 | News & Updates
InSitu Biologics was formally welcomed into in5, one of the UAE’s leading incubators, last month by in5’s Board of Directors. In5 specializes in supporting tech, media, and design startups. For more details about this development, please take some time to...
by InSitu Biologics | Dec 28, 2021 | News & Updates
InSitu Biologics is closing out 2021 with many accomplishments. We received positive pre-IND feedback from the FDA, made gains in process development work, published and presented INSB200™ data, and closed an additional institutional funding round. For additional...
